Open AccessDefinitive chemoradiotherapy in Stage III nonsmall cell lung cancer: Turkey experience
Author(s) -
Ufuk Yılmaz,
Ülkü Yılmaz,
Zehra Yaşar,
Esra Korkmaz Kıraklı,
Şükran Ülger,
Yasemin Özdoğan,
Nilgün Yılmaz Demirci,
Serhat Erol,
Ilker Ozdogan,
Burcu Şahin,
Deniz Köksal,
Cimen Akcay
Publication year - 2016
Publication title -
journal of cancer research and therapeutics/journal of cancer research and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 39
eISSN - 0973-1482
pISSN - 1998-4138
DOI - 10.4103/0973-1482.163682
Subject(s) - medicine , chemoradiotherapy , stage (stratigraphy) , radiation therapy , lung cancer , etoposide , cisplatin , confidence interval , gastroenterology , surgery , chemotherapy , oncology , paleontology , biology
Concurrent chemoradiotherapy (CRT) is the standard therapy for patients with unresectable Stage III nonsmall cell lung cancer (NSCLC). The aim of this study was to assess the efficacy and safety of concurrent CRT in unresectable Stage III NSCLC in Turkey.